<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548726</url>
  </required_header>
  <id_info>
    <org_study_id>MATCH-BALL</org_study_id>
    <nct_id>NCT04548726</nct_id>
  </id_info>
  <brief_title>Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis</brief_title>
  <acronym>MATCH-BALL</acronym>
  <official_title>Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignacio J. Amat Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is recommended for patients with severe aortic&#xD;
      stenosis (AS) at high to intermediate surgical risk. Despite similar mortality rates compared&#xD;
      to surgical aortic valve replacement (SAVR) in this setting, the rate para-valvular leak&#xD;
      (PVL) remains higher and has been associated to higher mortality even at mild degree. This is&#xD;
      one of the major concerns to extend TAVI to low surgical risk, although the favorable results&#xD;
      from PARTNER 3.&#xD;
&#xD;
      The presence of moderate to severe PVL after TAVI is associated to a 2- and 3- fold increase&#xD;
      in the mortality rate at 30-day and 1-year follow-up, respectively (24-29).&#xD;
&#xD;
      Prosthesis-patient mismatch (PPM) adversely affects functional improvement and exercise&#xD;
      tolerance, left ventricular (LV) mass regression, and late structural valve deterioration.&#xD;
      Many studies have previously investigated PPM after surgical AVR suggesting the presence of&#xD;
      this problem in more than 40% of the surgically treated patients. This rate was significantly&#xD;
      lower with the balloon-expandable Sapien (Edwards Lifesciences, Irvine, California), with PPM&#xD;
      that varied from 8% to 18%, but in both cases (patients harboring TAVI and those with SAVR)&#xD;
      the mortality rate was higher in the presence of PPM.&#xD;
&#xD;
      Under the hypothesis that there are differences in terms of transvalvular gradients and&#xD;
      residual para-valvular leak amongst different balloon-expandable TAVI devices available in&#xD;
      the market, the aim of the MATCH-BALL study is to compare the hemodynamic performance of two&#xD;
      balloon-expandable TAVI devices, Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) and Myval&#xD;
      (Meril Life Sciences Pvt. Ltd., India).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean transvalvular gradients</measure>
    <time_frame>30 days</time_frame>
    <description>Mean Gradients measured in doppler echography are calculated based on the mean velocity of the tracing. The velocities are converted to pressure gradients using the Bernoulli equation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic valve area</measure>
    <time_frame>30 days</time_frame>
    <description>Echography measured Aortic valve area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic valve perivalvular leak</measure>
    <time_frame>30 days</time_frame>
    <description>Echography measured perivalvular leak</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic valve central leak</measure>
    <time_frame>30 days</time_frame>
    <description>Echography measured central leak</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic valve global leak</measure>
    <time_frame>30 days</time_frame>
    <description>Echography measured global leak</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complications rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduction disorder rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for permanent pacemaker rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">416</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Sapien 3</arm_group_label>
    <description>Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myval</arm_group_label>
    <description>Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sapien 3 Transcather Aortic Valve Implant</intervention_name>
    <description>Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.</description>
    <arm_group_label>Sapien 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Myval Transcather Aortic Valve Implant</intervention_name>
    <description>Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.</description>
    <arm_group_label>Myval</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent TAVI with any of the previously explained self-expandable&#xD;
        devices in the participating institutions and have at least one transthoracic&#xD;
        echocardiography after TAVI procedure will be included. Main baseline and procedural&#xD;
        characteristics as well as in-hospital outcomes will be drawn from the prospective database&#xD;
        available at each institution.&#xD;
&#xD;
        Echocardiographic exams will be centrally analysed by two independent operators blinded to&#xD;
        the TAVI device and the clinical outcomes as well as to any clinical information of the&#xD;
        patients.&#xD;
&#xD;
        Subjects treated with each device will be matched with patients who had undergone&#xD;
        transcatheter aortic valve implantation with the alternative devices and clinical and&#xD;
        echocardiographic variables will be compared. The final matching will be performed by&#xD;
        random sampling without replacement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients diagnosed with aortic stenosis (effective aortic&lt;1.0 cm2) accepted for a&#xD;
             TAVI procedure by the Heart Team.&#xD;
&#xD;
          -  Implantation of Sapien-3 transfemoral valve or Myval transfemoral prosthesis.&#xD;
&#xD;
          -  Availability of the variables selected for the matching process: Left ventricular&#xD;
             ejection fraction, aortic annulus diameter and area, eccentricity index, and calcium&#xD;
             score (all measured using computed tomography), body surface area, and body mass&#xD;
             index.&#xD;
&#xD;
          -  Availability of imaging studies at baseline and at discharge or 30-day follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to comply with matching criteria.&#xD;
&#xD;
          -  Failure to properly analyse images in the echo core-lab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Segrate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr Negrin</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Ignacio J. Amat Santos</investigator_full_name>
    <investigator_title>Coordinator of Interventional Cardiology Unit</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>Balloon-Expandable transcatheter heart valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

